Fendiline anticancer activity was also reported by other groups, which reported that this drug interferes with the activation of ADAM 10 [26], blocks K-RAS signaling transmission [27], or evokes Ca++-triggered cell death in human oral, hepatoma, and female bladder transitional carcinoma cells [28,29,30]. This evidence concerns the gene KRAS and hepatocellular carcinoma.